Positive early Phase II data from ponatinib in leukaemia
This article was originally published in Scrip
Executive Summary
Ariad Pharmaceuticals has announced positive preliminary data from an ongoing Phase II trial investigating its pan-BCR-ABL Inhibitor, ponatinib, in patients with chronic myeloid leukaemia (CML) or Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL), who are resistant or intolerant to dasatinib or nilotinib or who have the T315I mutation.